Q-omics provides the consensus-scored FAM170B profile across patient tissues and cancer cell-line models. FAM170B expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, FAM170B is differentially expressed in 10, with the highest sampling consensus in KIRP. Additionally, FAM170B RNA expression shows 6,338 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight UCS, KIRP, and STAD as cancer lineages where FAM170B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM170B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM170B survival associations across molecular data types. FAM170B RNA expression shows survival associations in the most cancer types (20), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM170B RNA expression–survival associations across cancer types. High FAM170B expression shows unfavorable associations in KIRC, LIHC, MESO, LAML and UCEC, but favorable associations in UCS. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify UCS as the clearest survival context for FAM170B RNA expression.
This table summarizes FAM170B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for FAM170B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM170B shows lower tumor expression in KIRP, UCEC, BRCA, KICH, LUSC and PAAD. The KIRP box plot shows higher FAM170B RNA expression in normal versus tumor tissue (log2 FC = −0.090, t-test p < 0.001).
This table shows molecular features associated with FAM170B in patient tissues and cancer cell lines. In patient samples, FAM170B shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, FAM170B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and LARGE_INTESTINE.
